AngioDynamics (NASDAQ:ANGO) Issues Quarterly Earnings Results

Key Points

• AngioDynamics reported a quarterly earnings per share (EPS) of ($0.10), surpassing the consensus estimate of ($0.12), with revenues of $75.71 million, exceeding expectations.
• The company updated its FY 2026 guidance to an EPS range of -0.330 to -0.230.
• Several analysts upgraded AngioDynamics to a Buy rating, with price targets raised to as high as $24.00.

AngioDynamics (NASDAQ:ANGO - Get Free Report) posted its quarterly earnings results on Thursday. The medical instruments supplier reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.02, Zacks reports. AngioDynamics had a negative return on equity of 3.20% and a negative net margin of 11.62%.The firm had revenue of $75.71 million during the quarter, compared to analysts' expectations of $72.69 million. During the same quarter in the prior year, the firm posted ($0.11) EPS. The company's revenue for the quarter was up 12.1% on a year-over-year basis. AngioDynamics updated its FY 2026 guidance to -0.330--0.230 EPS.

AngioDynamics Stock Down 0.9%

AngioDynamics stock opened at $11.07 on Thursday. The stock has a 50-day simple moving average of $9.84 and a 200 day simple moving average of $9.73. The stock has a market capitalization of $454.76 million, a price-to-earnings ratio of -13.34 and a beta of 0.78. AngioDynamics has a 12-month low of $5.83 and a 12-month high of $13.50.

Analyst Upgrades and Downgrades

Several research analysts recently commented on ANGO shares. Wall Street Zen raised AngioDynamics from a "hold" rating to a "buy" rating in a research report on Saturday, August 16th. HC Wainwright reaffirmed a "buy" rating and set a $16.00 price objective on shares of AngioDynamics in a report on Wednesday, July 16th. Canaccord Genuity Group upped their target price on shares of AngioDynamics from $15.00 to $17.00 and gave the company a "buy" rating in a research note on Wednesday, July 16th. Finally, Lake Street Capital started coverage on shares of AngioDynamics in a research note on Wednesday, July 16th. They set a "buy" rating and a $24.00 price target for the company. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat, AngioDynamics currently has an average rating of "Buy" and an average price target of $19.00.

Institutional Trading of AngioDynamics

Hedge funds have recently modified their holdings of the stock. State of Wyoming bought a new position in AngioDynamics in the 2nd quarter worth approximately $31,000. Tower Research Capital LLC TRC raised its position in shares of AngioDynamics by 359.0% during the second quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier's stock worth $54,000 after acquiring an additional 4,268 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of AngioDynamics during the second quarter valued at $90,000. Legal & General Group Plc boosted its holdings in AngioDynamics by 279.5% in the second quarter. Legal & General Group Plc now owns 12,353 shares of the medical instruments supplier's stock valued at $123,000 after acquiring an additional 9,098 shares during the last quarter. Finally, Massar Capital Management LP bought a new stake in AngioDynamics during the 2nd quarter worth about $278,000. 89.43% of the stock is owned by institutional investors.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.